Premium
Replimune Group Inc (REPL)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. I... Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.495 | 28.017967434 | 8.905 | 12.23 | 8.625 | 2886343 | 10.19631416 | CS |
| 4 | 6.41 | 128.456913828 | 4.99 | 12.23 | 4.47 | 6497893 | 8.82628963 | CS |
| 12 | 4.05 | 55.1020408163 | 7.35 | 12.23 | 1.5 | 8117577 | 4.77043303 | CS |
| 26 | 1.48 | 14.9193548387 | 9.92 | 12.23 | 1.5 | 4496358 | 5.26340529 | CS |
| 52 | 2.24 | 24.4541484716 | 9.16 | 13.24 | 1.5 | 5752019 | 6.02814203 | CS |
| 156 | -11.91 | -51.093951094 | 23.31 | 24.28 | 1.5 | 2599206 | 7.13513244 | CS |
| 260 | -23.95 | -67.7510608204 | 35.35 | 40.22 | 1.5 | 1705820 | 8.47337619 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
